Google
CING — CINGULATE INC (Healthcare >> Biotechnology)
CING FAQ
What is CING's ROE?
CINGULATE INC reports a Return on Equity (ROE) of -146.91%.
What is CING's dividend yield?
CINGULATE INC offers a dividend yield of 0.00%.
What is CING's Deepscope Quality Score?
Deepscope rates CING's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CING?
Deepscope's AI Timing Score for CING is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CING belong to?
CINGULATE INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.03
Price
0.85
(21.09%)
Day Change
|
|
|---|
CING, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.03 |
| PBV / Sector |
3.02 / 4.53
|
| Earning Per Share | -1.96 |
| PE / Sector |
N/A / 16.80
|
| PEG or PE/Growth / Sector |
N/A / 0.51
|
| Average 1M Daily Value |
3.68 M
GREAT
|
| Average 1W Daily Value |
7.67 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-03 09:11:47 |
| Symbol | CING |
| Name | CINGULATE INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 13.47 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 57.06 / 8,614.17 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1901 West 47th Place, Kansas City, KS, United States, 66205
Phone: 913 942 2300
Website: https://www.cingulate.com
Sector: Healthcare >> Biotechnology
Description: Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
